More than 85% of patients have significant genetic variations in the most important cytochromes – CYP2D6, CYP2C9, CYP2C19, CYP3A4 and CYP3A5. For example, CYP3A4 and CYP3A5 affect the metabolism of one-half of the drugs in clinical use, and this variance is profoundly affected based on patient ethnicity.
Genetic Variations in Cytochromes Affect Drug Metabolism
How Genelex can help detect your metabolism type
Genelex, powered by YouScript Precision Prescribing software, tests these cytochromes (CYPs), which are responsible for metabolizing most commonly prescribed medications. Once tested, each patient is classified as a Poor, Intermediate, Normal, Rapid, or Ultra-rapid Metabolizer. These classifications describe a patient’s inherent drug metabolizing capacity, a major contributor to adverse drug events.
|Gene||Poor Metabolizer||Intermediate Metabolizer||Normal Metabolizer||Rapid or Ultrarapid Metabolizer|
*CYP2C19 variability depends on ethnicity.
Effects That May Be Seen In Patients
*Prodrugs must be metabolized in order to become active.
Until recently – you had little choice but to try medication to understand how it will affect you. But no more, with Genelex’s pharmacogenetic testing you can know upfront what medications will likely be the most effective. Additionally – by utilizing YouScript’s precision prescribing platform – you can audition or try out different medications based on a patient’s unique genetic characteristics and current medication regimen to see if that drug is likely to work for them.